Ann: FY20 Annual Report to shareholders, page-51

Hi Clyde, I think no one doubts MB is working hard. It’s way over time to be pragmatic about this company as what has it really got?? Artimist is worthless, Zolpimist doesn’t seem to be getting anywhere fast... The rest of the products other than anagrelide either parked or stalled, so, it would be fair to say if at all, the company is still years off anything significant. As for the latest acquisition attempt, that may have provided an opportunity to exit for some had it had gone ahead, reality is, it didn’t so we are no farther afield.
Biotech is notoriously slow and relies on blind faith to keep tipping money in to fund hope.
Without updates/ detailed communication etc, it is almost impossible to maintain a positive view.